The observed reductions in AR mRNA and protein levels in two PCa cell lines (Fig. 1) confirm the feasibility and therapeutic relevance of siRNA-LNPs for modulating the AR pathway, which is a key driver of prostate cancer progression (Heinlein and Chang, 2004). The gene discussed is AR; the disease is prostate carcinoma.